Overview: Hemoglobinopathy Newborn Panel
Introduction: The Hemoglobinopathy Newborn Panel is a diagnostic tool designed for newborn hemoglobinopathy screening using whole blood samples. In India, hemoglobinopathies (beta-thalassemia major, sickle cell disease) affect ~100,000 newborns annually (~40 million carriers), with high prevalence in tribal and northern regions. Early screening prevents severe anemia, transfusion dependence, and mortality. High burden from under-screening in rural/low-SES newborns, limited newborn screening programs, delayed diagnosis leading to growth failure or death by age 5 in untreated thalassemia major. Per hematology practices aligned with ICMR and National Thalassemia Control Programme guidelines, the test employs electrophoresis for HbF, HbA, HbS, HbC over 1-2 days with high accuracy, valuable for identifying major hemoglobinopathies at birth. This diagnostic falls under newborn screening and targets all newborns (universal in high-prevalence areas), addressing accurate detection to guide early transfusion/chelation or genetic counseling. With elevated morbidity due to under-screening, the test supports public health efforts by enabling timely intervention and reducing hemoglobinopathy mortality. Its whole blood-based approach ensures reliable variant identification.
Other Names: Hb Newborn Pnl.
FDA Status: FDA approved, CLIA certified for hematology/molecular pathology, compliant with 2025 standards.
Historical Milestone: Newborn Hb screening expanded; in India, piloted in high-prevalence states.
Purpose: The test assesses 4 parameters including HbF to guide newborn hemoglobinopathy screening, detect major variants, inform early management.
Test Parameters: 1. HbF, 2. HbA, 3. HbS, 4. HbC.
Pretest Condition: No fasting required; patients should be newborns.
Specimen: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve cell integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for electrophoresis).
Medical History: Parents should provide details on ethnicity, family history of anemia.
Consent: Written informed consent from parents is required, detailing the test's purpose, potential risks of undetected hemoglobinopathy including severe anemia, benefits of early detection, and minimal discomfort from heel prick/blood draw.
Procedural Considerations: The test involves sample processing using electrophoresis by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or recent transfusion can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal Hb pattern indicates hemoglobinopathy, necessitating specialist input. Normal may require follow-up in high-risk.
Specialist Consultation: Pediatric hematologists should be consulted for management.
Additional Supporting Tests: DNA analysis, HPLC for confirmation.
Test Limitations: May miss rare variants; comprehensive approach required.
References: Indian Journal of Pediatrics 2024, Hemoglobinopathy Studies India 2023.
